Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Santa Ana, CA
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Torrance, CA
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
New Haven, CT
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Atlanta, GA
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Marietta, GA
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Chicago, IL
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Wichita, KA
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Cedarhurst, NY
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Rochester, NY
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Staten Island, NY
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Philadelphia, PA
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Dallas, TX
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Desoto, TX
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Desoto, TX
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Houston, TX
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated:  10/16/2013
Clinical Research Facility
mi
from
Houston, TX
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
Status: Enrolling
Updated: 10/16/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia
Status: Enrolling
Updated:  11/2/2013
Semel Institute for Neuroscience and Human Behavior at UCLA
mi
from
Los Angeles, CA
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia
Status: Enrolling
Updated: 11/2/2013
Semel Institute for Neuroscience and Human Behavior at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
A Randomized Single-Blind, Placebo-Controlled, Ascending Single Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia.
Status: Enrolling
Updated:  11/26/2013
California Clinical Trials Medical Group
mi
from
Glendale, CA
A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
A Randomized Single-Blind, Placebo-Controlled, Ascending Single Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia.
Status: Enrolling
Updated: 11/26/2013
California Clinical Trials Medical Group
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
A Randomized Single-Blind, Placebo-Controlled, Ascending Single Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia.
Status: Enrolling
Updated:  11/26/2013
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
A Randomized Single-Blind, Placebo-Controlled, Ascending Single Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia.
Status: Enrolling
Updated: 11/26/2013
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Baltimore VA Medical Center
mi
from
Baltimore, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Baltimore VA Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Community Mental Health Centers
mi
from
Baltimore, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Community Mental Health Centers
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Keypoint Community Mental Health Centers
mi
from
Baltimore, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Keypoint Community Mental Health Centers
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Keypoint Mental health Center
mi
from
Dundalk, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Keypoint Mental health Center
mi
from
Dundalk, MD
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated:  12/12/2013
Maryland Psychiatric Research Center
mi
from
Catonsville, MD
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Status: Enrolling
Updated: 12/12/2013
Maryland Psychiatric Research Center
mi
from
Catonsville, MD
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
Johns Hopkins University
mi
from
Baltimore, MD
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
University of Maryland
mi
from
Baltimore, MD
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
Univ of North Carolina
mi
from
Chapel Hill, NC
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
A Randomized Single-Blind, Placebo-Controlled, Ascending Multiple Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
Status: Enrolling
Updated:  12/18/2013
California Clinical Trials Medical Group
mi
from
Glendale, CA
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
A Randomized Single-Blind, Placebo-Controlled, Ascending Multiple Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
Status: Enrolling
Updated: 12/18/2013
California Clinical Trials Medical Group
mi
from
Glendale, CA
Click here to add this to my saved trials
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
A Randomized Single-Blind, Placebo-Controlled, Ascending Multiple Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
Status: Enrolling
Updated:  12/18/2013
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
A Randomized Single-Blind, Placebo-Controlled, Ascending Multiple Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
Status: Enrolling
Updated: 12/18/2013
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia
Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia
Status: Enrolling
Updated:  12/20/2013
VA West Los Angeles Healthcare Center
mi
from
Los Angeles, CA
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia
Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia
Status: Enrolling
Updated: 12/20/2013
VA West Los Angeles Healthcare Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Subjects With Stable Schizophrenia and Healthy Japanese Subjects
Status: Enrolling
Updated:  12/20/2013
Clinical Research Facility
mi
from
Glendale, CA
Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Subjects With Stable Schizophrenia and Healthy Japanese Subjects
Status: Enrolling
Updated: 12/20/2013
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
A Phase I, Prospective, Randomized, Double-blind, Placebo-controlled, Sequential-cohort, Escalating, Single-dose Study Designed to Determine the Maximum Tolerated Oral Dose of NW-3509A in Healthy, Male Volunteers.
Status: Enrolling
Updated:  1/17/2014
Collaborative Neuroscience Network-Clinical Pharmacology Unit
mi
from
Long Beach, CA
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
A Phase I, Prospective, Randomized, Double-blind, Placebo-controlled, Sequential-cohort, Escalating, Single-dose Study Designed to Determine the Maximum Tolerated Oral Dose of NW-3509A in Healthy, Male Volunteers.
Status: Enrolling
Updated: 1/17/2014
Collaborative Neuroscience Network-Clinical Pharmacology Unit
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers
Status: Enrolling
Updated:  1/21/2014
Pfizer Investigational Site
mi
from
New Haven, CT
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers
Status: Enrolling
Updated: 1/21/2014
Pfizer Investigational Site
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers
Status: Enrolling
Updated:  1/21/2014
Pfizer Investigational Site
mi
from
West Haven, CT
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers
Status: Enrolling
Updated: 1/21/2014
Pfizer Investigational Site
mi
from
West Haven, CT
Click here to add this to my saved trials
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Status: Enrolling
Updated:  2/3/2014
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Status: Enrolling
Updated: 2/3/2014
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
mi
from
Little Rock, AR
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational site
mi
from
Culver City, CA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational site
mi
from
Culver City, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Escondito, CA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Escondito, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Garden Grove, CA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
National City, CA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
National City, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Oakland, CA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Oakland, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Oceanside, CA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Orange, CA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Pico Rivera, CA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Pico Rivera, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
San Diego, CA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Torrance, CA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
New Britain, CT
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
New Britain, CT
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
mi
from
Washington,
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
mi
from
Washington,
Click here to add this to my saved trials